Inovio Pharmaceuticals Inc (INO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.43+5.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 66.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
INO — debt issuance
Dated 2026-07-31
Entry into a Material Definitive Agreement. On July 29, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co., as underwriter (the “ Underwriter ”), relating to the issuance and sale by the Company in a public offering of (i) 21,052,632 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and (ii) accompanying warrants (the “ Warrants ”) to purch…
Why it matters: Higher cash burn could signal financial strain and impact future funding needs. It may affect investor confidence.
Worry ifOperational cash burn reported at or below $18 million for Q3 2026.
Less concerning ifOperational cash burn exceeds $22 million for Q3 2026.
Why it matters: Good results may lead to approval and revenue from VGX-3100 in an important market.
Supportive ifApolloBio files for VGX-3100 approval based on good trial results.
Worry ifWatch for ApolloBio. They had bad trial results for VGX-3100. This may hurt future approvals.
Why it matters: The earnings report will show revenue and costs. This affects how investors feel.
Watch forEarnings report shows revenue is growing or costs are better managed.
Also watch forEarnings report shows ongoing losses or costs are higher than expected.
Why it matters: Successful commercial plans could enhance revenue potential if INO-3107 is approved. Delays could hurt market entry.
Supportive ifManagement says they completed key steps for INO-3107's readiness to sell.
Worry ifManagement reports issues with plans for INO-3107's readiness to sell.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$223 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $623 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,714 loss on $10,000 · 77.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Earnings results will provide insights into financial health and operational progress. Poor results could raise concerns.
Watch forEarnings report shows revenue was better than expected and cash burn went down.
Also watch forEarnings report shows revenue was worse than expected and cash burn went up.
Why it matters: If healthcare sector revenue growth speeds up, it could benefit Inovio's performance.
Supportive ifHealthcare sector revenue growth speeds up toward 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing below current levels.
Why it matters: Issuing debt could provide needed funds for operations. It can also signal confidence in future growth.
Supportive ifA public announcement about a debt issuance plan for capital use.
Worry ifNo announcement of debt issuance or plans to raise capital in the next quarter.
Why it matters: The FDA's decision will determine if INO-3107 can be launched. This is crucial for INOVIO's future.
Supportive ifFDA approves the BLA for INO-3107 on or before October 30, 2026.
Worry ifFDA denies the BLA for INO-3107 or delays the decision past October 30, 2026.
Why it matters: How well the public offering goes will affect INOVIO's cash and operations. This is key for liquidity.
Watch forThe public offering is done successfully and raises enough funds.
Also watch forThe offering does not get enough interest or is delayed a lot.
Why it matters: Successful preparations show confidence in getting approval. This helps gain market share fast.
Supportive ifINOVIO announces partnerships and plans for the launch of INO-3107.
Worry ifThere are reports of delays in launch preparations.
Why it matters: Feedback on the trial design is crucial for INO-3107's path to approval and future studies.
Watch forFDA gives positive feedback on the trial design for INO-3107.
Also watch forFDA raises concerns about the trial design and wants major changes.